

 PROCEDURES FOR PRIOR AUTHORIZATION

Completed forms can be faxed in confidence to 1-514-286-8480 for residents of Quebec and 1-844-661-2640 for residents of all other provinces

Upon receipt, this request will be confidentially reviewed according to payment criteria developed by Medavie Blue Cross in consultation with independent health care consultants. In some cases, additional clinical or diagnostic information may be required to process your claim.

For Quebec residents, the criteria for prior authorization are adjusted to meet the requirements of the Régie de l'assurance maladie du Québec (RAMQ).

- Prior Authorization is a pre-approval process to determine if certain products will be reimbursed under a member's benefit plan.
- Please complete entire form. Incomplete forms cannot be processed.
- **For certain medications, approval for reimbursement may be conditional on confirmation of enrollment in the patient support program.**
- Prior Authorization may be limited to a specified period or quantity of medication. Some Medavie Blue Cross plans may require you to purchase a drug requiring prior authorization from a preferred pharmacy\*. If your prior authorization request is approved, a case manager may contact you, your physician, or Patient Assistance Program to provide information about the program and to arrange to have your prescription transferred to the preferred pharmacy.  
*\*Not applicable in Quebec.*
- In cases where a request for Prior Authorization is declined, Medavie Blue Cross is denying payment for a product and is not challenging the medical opinion of the physician nor rendering a medical opinion.
- Any costs associated with the completion of this form or obtainment of additional medical information are the responsibility of the member.
- Renewal of the Prior Authorization will be considered by Medavie Blue Cross upon request from the patient/member. The renewal request should include information from the physician supporting continued use of the medication.
- Prior Authorization coverage is contingent on your continued status as a Medavie Blue Cross cardholder or beneficiary.
- If this is a request under the *Mesure du patient d'exception* for a Quebec resident, please include a completed *Patient d'exception* form that can be found here: [www.medaviebc.ca/en/resources](http://www.medaviebc.ca/en/resources), in addition to this document.
- If you would like more information about our Patient First Network, including how your Patient Support Program can become integrated with our new enhanced Prior Authorization processes, please send an e-mail to: [patientfirstnetwork@medavie.bluecross.ca](mailto:patientfirstnetwork@medavie.bluecross.ca).

**Residents of All Other Provinces**  
PO BOX 220, MONCTON (NB) E1C 8L3  
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

**Residents of Quebec**  
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5  
TEL.: 1-888-588-1212 FAX: 1-514-286-8480

## 1 PHARMACY INFORMATION

This section is to be completed by the Professional coordinating the request on behalf of the member (PSP, Cancer Care Navigator or Pharmacy)

Decision communication preference: ☐ Fax, Number: \_\_\_\_\_ ☐ Telephone, Number: \_\_\_\_\_

Name of Program/Pharmacy: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Contact E-mail: \_\_\_\_\_

## 2 PATIENT INFORMATION

### Part A

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
(mm/dd/yyyy)

E-mail address of patient (or of legal guardian if patient is underage): \_\_\_\_\_

Address: \_\_\_\_\_ Suite: \_\_\_\_\_ City: \_\_\_\_\_

Province: \_\_\_\_\_ Postal Code: \_\_\_\_\_ Telephone Number: \_\_\_\_\_

Policy Number: \_\_\_\_\_ ID Number: \_\_\_\_\_

Do you have valid Medicare coverage in your current province of residence? ☐ Yes ☐ No

Have you already purchased this prescription? ☐ Yes ☐ No

Please attach your paid-in-full receipt with this request form. If you have already submitted your receipt to Medavie Blue Cross, please indicate the date of the oldest receipt. Date: \_\_\_\_\_  
(mm/dd/yyyy)

### Part B – Coordination of Benefits

Do you or any dependant have coverage for this drug under any other plan or program? ☐ Yes ☐ No If Yes, complete the following:

Policy Number: \_\_\_\_\_ Carrier: \_\_\_\_\_  
(If applicable, please attach Explanation of Benefits from prior carrier with complete form)

If the patient is a dependent, provide the birth day and month of the cardholder for the other carrier: \_\_\_\_\_  
(mm/dd)

Public-Funded Program – Have you applied for coverage through a public-funded program? ☐ Yes ☐ No

If No, please indicate why: \_\_\_\_\_

### Part C – Authorization

I understand that the personal information I have provided herein is collected and used by Medavie Blue Cross to administer the terms of my policy or the group policy of which I am an eligible member, recommend suitable products and services that I am eligible for as a member of a policy, and other applicable purposes, as described in the Medavie Blue Cross Privacy Statement at [www.medaviebc.ca](http://www.medaviebc.ca).

Depending on the type of coverage I carry, limited personal information such as claim, health and/or financial related data may be collected from and/or released to following third parties as required for the purposes of administering and managing the benefits outlined in the policy of which I am an eligible member. These third parties may include healthcare providers, other insurance companies, regulatory authorities and investigative bodies, services providers, and/or the cardholder of any contract under which I am a participant.

Where allowed by law, my information may be shared with Medavie Blue Cross employees or service providers in jurisdictions other than where it was collected. If I am a resident of Quebec, this includes transferring or disclosing my personal information to Medavie Blue Cross employees or service providers outside of that province.

I understand that my consent is only valid for the time it is needed to achieve the purposes outlined herein, unless I withdraw it. I understand I may withdraw my consent at any time. However, in some instances doing so may prevent Medavie Blue Cross from providing me with certain products or services that may be useful to me and/or my dependents. This consent complies with federal and provincial privacy laws.

For more details about our information practices, including how your personal information is protected, how to access or correct personal information, or if you have concerns or questions, please see our Medavie Blue Cross Privacy Statement available at [www.medaviebc.ca](http://www.medaviebc.ca) or call 1-800-667-4511.

Signature of Patient: \_\_\_\_\_

Date: \_\_\_\_\_  
(mm/dd/yyyy)

**Residents of All Other Provinces**  
PO BOX 220, MONCTON (NB) E1C 8L3  
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

**Residents of Quebec**  
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5  
TEL.: 1-888-588-1212 FAX: 1-514-286-8480



**3 SPECIALTY DRUG INFORMATION**

Name of patient: \_\_\_\_\_ Date of Birth : \_\_\_\_\_  
 Policy Number: \_\_\_\_\_ ID Number: \_\_\_\_\_

**3A Patient Support Program (PSP) Enrollment**

Is patient enrolled in the Patient Support Program? ☐ No ☐ Yes, specify Program ID #: \_\_\_\_\_

Indicate the name of the Patient Support Program: \_\_\_\_\_

PSP phone #: \_\_\_\_\_ PSP Fax #: \_\_\_\_\_

| Product Name                  | Strength | Dosage | Diagnosis |
|-------------------------------|----------|--------|-----------|
| <b>COTELLIC (COBIMETINIB)</b> |          |        |           |

Patient weight: \_\_\_\_\_ ☐ lbs ☐ kg Number of vials per dose: \_\_\_\_\_

Expected duration of therapy: \_\_\_\_\_ Date of diagnosis: \_\_\_\_\_  
 (mm/dd/yyyy)

Was treatment initiated in hospital? ☐ Yes ☐ No

Where is medication being administered? \_\_\_\_\_

Indicate the specialty of the physician who initiated or recommended the treatment: \_\_\_\_\_

**For Initial Request, please complete Section 3B. For Renewals, please complete Section 3C.**

**3B Initial Request**

**Please list all the drugs that were previously tried, or could not be tried because of contraindication. The information for the following drug categories (relative to each diagnosis) must be provided, including details on the contraindication if applicable.**

- **Melanoma: chemotherapy, immunotherapy targeting the PD-1 or the CTLA-4, BRAF inhibitor, MEK inhibitor, dacarbazine, ipilimumab (Yervoy™), nivolumab (Opdivo™)**

| Category | Product Name | Dosage | Duration of Treatment | Response to Treatment or Contraindication |
|----------|--------------|--------|-----------------------|-------------------------------------------|
|          |              |        |                       |                                           |
|          |              |        |                       |                                           |
|          |              |        |                       |                                           |
|          |              |        |                       |                                           |
|          |              |        |                       |                                           |
|          |              |        |                       |                                           |

**Is the drug being prescribed according to the Health Canada product monograph?** ☐ Yes ☐ No

**1. Melanoma**

Pharmacological treatment: ☐ First-line treatment ☐ Second-line treatment ☐ Third-line treatment or more

Administration of treatment: ☐ In monotherapy

☐ In association with vemurafenib

☐ In association with another medication. Specify: \_\_\_\_\_

ECOG score (date): \_\_\_\_\_ (\_\_\_\_\_)  
 (mm/dd/yyyy)

Indicate if the melanoma is: ☐ Metastatic ☐ Unresectable ☐ Other. Specify: \_\_\_\_\_

Indicate the stage of the melanoma: \_\_\_\_\_

Indicate if the patient is BRAF V600 mutation positive\*: ☐ Yes ☐ No

*\*NOTE: Do not provide genetic test results*

**3 SPECIALTY DRUG INFORMATION**

Name of patient: \_\_\_\_\_ Date of Birth : \_\_\_\_\_  
Policy Number: \_\_\_\_\_ ID Number: \_\_\_\_\_

**3B Initial Request (cont'd)****1. Melanoma (cont'd)**

Indicate if there are brain metastases: ☐ Yes ☐ no

↳ If the answer is yes, → indicate if they are symptomatic: ☐ Yes ☐ No

→ indicate if they are stable: ☐ Yes ☐ No

**2. Please indicate any additional information pertaining to this request****3C Renewal Request**

**Please provide information on the evolution of the disease to evaluate the response to treatment**

Date of initial evaluation (pre-treatment): \_\_\_\_\_ Date of most recent evaluation: \_\_\_\_\_  
(mm/dd/yyyy) (mm/dd/yyyy)

**1. Melanoma**

Indicate if there is evidence of disease progression: ☐ Yes ☐ No

↳ Confirmed by : ☐ Physical examination ☐ Imaging (date of last imaging) : \_\_\_\_\_  
(mm/dd/yyyy)

Please provide any additional data showing the beneficial effect of the treatment:

**i HEALTH PROFESSIONAL STATEMENT**

I certify that I have reviewed all pages of this request and that all information provided is true, correct and complete.

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_ Permit Number: \_\_\_\_\_

Specialty: \_\_\_\_\_

Clinic Name: \_\_\_\_\_

Address: \_\_\_\_\_ Suite: \_\_\_\_\_

City: \_\_\_\_\_ Province: \_\_\_\_\_ Postal Code: \_\_\_\_\_

E-mail: \_\_\_\_\_ Telephone: \_\_\_\_\_ Fax: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

(mm/dd/yyyy)

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit.

**Residents of All Other Provinces**

PO BOX 220, MONCTON (NB) E1C 8L3  
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

**Residents of Quebec**

PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5  
TEL.: 1-888-588-1212 FAX: 1-514-286-8480